Scorpion Therapeutics

NEWS
Scorpion Therapeutics is on a mission to create a world where many more cancer patients can benefit from precision therapies. Earlier this year, it struck a $75 million alliance with AstraZeneca.
Biopharma companies are preparing to unveil new data for various oncology programs at the American Association for Cancer Research (AACR) Annual Meeting in New Orleans next month.
The companies believe the collaboration, valued at more than $1.5 billion, for up to three small molecule therapeutics has the potential to transform oncology treatments.
BioSpace is proud to present its NextGen Bio “Class of 2022,” a list of up-and-coming life sciences companies in North America that recently launched.
Scorpion Therapeutics announced its new CEO Dr. Axel Hoos while Tenax Therapeutics named Christopher Giordano as its new chief executive.
This week multiple companies have announced millions of investment dollars have flooded their coffers to advance research and development of multiple therapies. BioSpace is rounding up the announcements.
AWARDS
  • NextGen Class of 2022
IN THE PRESS
Scorpion Therapeutics, Inc. announced leadership changes intended to position the Company for its next phase of growth, including the appointment of Adam Friedman, M.D., Ph.D., as Chief Executive Officer.
Scorpion Therapeutics, Inc. today announced the appointment of Jeff Albers as a strategic advisor to the company.
Scorpion Therapeutics, Inc announced preclinical data for STX-241, an orally bioavailable, highly selective, central nervous system -penetrant and potentially best-in-class fourth generation epidermal growth factor receptor tyrosine kinase inhibitor designed to inhibit C797S mutations with a co-occurring EGFR exon 19 deletion or exon 21 mutation in non-small cell lung cancer.
Scorpion Therapeutics, Inc. and Pierre Fabre Laboratories announced that the first patient has been dosed in a Phase 1/2 first-in-human dose escalation and expansion clinical trial evaluating STX-721, Scorpion’s highly differentiated, orally bioavailable, irreversible highly selective tyrosine kinase inhibitor targeting epidermal growth factor receptor and ERBB2 Exon 20 insertion mutations, well-known, clinically validated oncogenic drivers in non-small cell lung cancer.
Scorpion Therapeutics, Inc. today announced that the first patient has been dosed in a Phase 1/2 first-in-human dose escalation and expansion clinical trial evaluating STX-478.
Scorpion Therapeutics, Inc. (“Scorpion”) today announced an exclusive collaboration and license agreement for the co-development of STX-721 and STX-241, two candidates in Scorpion’s franchise of highly-selective, next-generation mutant epidermal growth factor receptor (“EGFR”) inhibitors.
Scorpion Therapeutics, Inc. (“Scorpion”), a clinical-stage biotechnology company redefining the frontier of precision medicine through its Precision Oncology 2.0 strategy, today announced that it has named STX-241 as its next development candidate.
Scorpion Therapeutics Presents Preclinical Data for Potential Best-in-Class PI3K α Inhibitor at San Antonio Breast Cancer Symposium.
Scorpion Therapeutics, Inc. (“Scorpion”), a pioneering oncology company redefining the frontier of precision medicine through its Precision Oncology 2.0 strategy, today announced that it will present preclinical data on STX-478, its potential best-in-class mutant-selective PI3Kα inhibitor, in a poster session at San Antonio Breast Cancer Symposium (“SABCS”) in San Antonio, Texas, taking place December 6 – 10, 2022.
Scorpion Therapeutics, Inc., a pioneering oncology company redefining the frontier of precision medicine through its Precision Oncology 2.0 strategy, announced the formation of its Clinical Scientific Advisory Board.